# PF-07248144

Source: https://onco.cc/drugs/pf-07248144/  
OnCo record `pf-07248144` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PF-07248144 is an experimental small-molecule drug from Pfizer in phase 3 trials for HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer, with its target not yet stated publicly.

## Summary

PF-07248144 is a small-molecule drug developed by Pfizer. The sponsor describes its target as KAT6 (lysine acetyltransferase, e.g. KAT6A), which OnCo does not yet have a target page for. The sponsor states: PF-07248144 is a KAT6 inhibitor being studied as a single agent and in combination with fulvestrant, letrozole plus palbociclib, PF-07220060 (a CDK4 inhibitor) plus fulvestrant, or vepdegestrant, in HR-positive/HER2-negative breast cancer and other solid tumours. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07062965 (A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment), in HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer. The largest, NCT07062965, plans to enrol 400 participants with primary completion expected 2027-07-22. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: PF-07248144 is a KAT6 inhibitor being studied as a single agent and in combination with fulvestrant, letrozole plus palbociclib, PF-07220060 (a CDK4 inhibitor) plus fulvestrant, or vepdegestrant, in HR-positive/HER2-negative breast cancer and other solid tumours.

## Sources

- ClinicalTrials.gov: trials of PF-07248144: https://clinicaltrials.gov/search?intr=PF-07248144

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- trials: [A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment](https://onco.cc/trials/nct07062965/), [Study of PF-07248144 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04606446/)

---
JSON: https://onco.cc/api/v1/entities/pf-07248144.json